TENAX THERAPEUTICS, INC. (TENX)
2025-06-30 | ||||
|---|---|---|---|---|
| Other income (expense), net | -9 | |||
| Research and development | 6,121 | |||
| General and administrative | 5,671 | |||
| Total operating expenses | 11,792 | |||
| Net operating loss | -11,792 | |||
| Interest income | 954 | |||
| Net loss | -10,847 | |||
| Earnings per share, basic | -0.27 | |||
| Earnings per share, diluted | -0.27 | |||
| Weighted average number of shares outstanding, basic | 39,572,177 | |||
| Weighted average number of shares outstanding, diluted | 39,572,177 | |||